Bioam Gestion
VC Fund
Paris, France
Bioam Gestion is a venture capital firm that offers a range of credit, insurance, and tax exemption services to its clients.Credit consists of credit repurchase, real estate credit, and consumer credit. Insurance consists of mutual health, life insurance, animal insurance, and prevention. Tax exemption consists of penal law and LMNP.BioamGestion was founded in 2000 and is based in Paris.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Bioam Gestion invests in
Stages Bioam Gestion invests in
Countries Bioam Gestion invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $2.2M–$31M
Investment Focus
Industry
- Biotechnology 6 (60%)
- Therapeutics 4 (40%)
- Health Care 3 (30%)
- Manufacturing 2 (20%)
- Medical Device 2 (20%)
Stage
- Series B 5 (50%)
- Seed 1 (10%)
- Series A 1 (10%)
- Series C 1 (10%)
- Series D 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Philippe Boucheron
Investment Director
|
Investment Director | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SuperSonic Imagine
|
SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $37.8M / Series C / Nov 29, 2010 | |
Cytheris
|
Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such aschemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). | $15M / Series D / Jun 07, 2010 | |
|
SuperSonic Imagine
|
SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $21.9M / Series B / Oct 23, 2008 | |
TxCell
|
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technologyplatform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients. | $11.5M / Series B / Feb 01, 2008 | |
Adocia
|
Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was founded in 2005 as Proteins & Peptides Management S.A.S. and changed its name to Adocia in January 2008. Adocia is based in Lyons, France. | $13.2M / Jan 21, 2008 | |
|
Cytheris
|
Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such aschemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). | $30.7M / Series B / Oct 25, 2006 | |
|
SuperSonic Imagine
|
SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $11M / Series A / Mar 01, 2006 | |
IntegraGen
|
IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platformsto provide genomics services to the pharmaceutical industry, biotech firms and other research providers. | $8.8M / Series B / Nov 17, 2005 | |
Pharma Omnium
|
Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products. | $2.2M / Series B / May 01, 2004 | |
Ademtech
|
Ademtech is developing and manufacturing superparamagnetic nanoparticles for in vitro diagnostic and life sciences applications. The association of complementary skills such as physicochemistry, polymer chemistry, immunology, cellular biology, molecular biology, and virology leads to the development of novel nano-objects with uniquecharacteristics. Ademtech offers magnetic media, instruments (thermoshaker, an electronic pipette with variable spacing) and automata (extraction and pipetting). It was founded in 2000 and is headquartered in Pessac, France. | Seed / Jan 01, 2001 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bioam Gestion invest in?
Bioam Gestion invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Seed stage. Most of the 10 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bioam Gestion's check size?
Bioam Gestion typically joins rounds of $2.2M–$31M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bioam Gestion participates in.
How do I contact Bioam Gestion?
Public channels for Bioam Gestion include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bioam Gestion?
The team at Bioam Gestion includes Philippe Boucheron (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
